FDA Moves To Crack Down on Misleading Drug Ads

Oops! Subscribers must be logged in to access this content.

Not A Thompson FDA Subscriber?

Unlock access to the benefits below with a no-cost, risk-free trial of the FDA Compliance Expert Suite.

Subscription Benefits

Start Your Free Trial

By signing up for a tour of the Thompson FDA Compliance Expert Suite, you are also registering to receive email offers and product updates from us. Simply click unsubscribe at the bottom of any email if you would like to discontinue delivery.

FDA Moves To Crack Down on Misleading Drug Ads

J.W. Schomisch

September 10, 2025 at 05:08 PM EST

The FDA announced that it is sending thousands of letters to drug companies and issuing approximately 100 cease-and-desist letters to companies with allegedly deceptive ads as part of a push to rein in what the agency considers to be misleading direct-to-consumer (DTC) pharmaceutical advertisements. In addition, the agency will initiate rulemaking to close what it termed the ... Read More

My Research Folders

You are not Logged in yet, Please login to see Your research folders.

Oops! Subscribers must be logged in to access this content.

Not A Thompson FDA Subscriber?

Unlock access to the benefits below with a no-cost, risk-free trial of the FDA Compliance Expert Suite.

Subscription Benefits

Start Your Free Trial

FDA Moves To Crack Down on Misleading Drug Ads

My Research Folders

THOMPSON FDA

COMPLIANCE EXPERT

RESOURCES

HELP

CONTACT